KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2016 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
KALV on Nasdaq
Shares outstanding
50,580,036
Price per share
$14.94
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
66,956,279
Total reported value
$1,081,355,139
% of total 13F portfolios
0%
Share change
+6,289,658
Value change
+$110,690,698
Number of holders
160
Price from insider filings
$14.94
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 9.9% $63,650,358 4,941,798 TANG CAPITAL MANAGEMENT, LLC 31 Mar 2025
Frazier Life Sciences Public Fund, L.P. 6.9% +42% $42,222,226 +$12,986,864 3,466,521 +44% Frazier Life Sciences Public Fund, L.P. 01 Nov 2025
Capital World Investors 6.4% $40,927,321 3,177,587 Capital World Investors 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 5.9% +18% $39,595,019 +$5,780,725 2,963,699 +17% Millennium Management LLC 23 Dec 2025
Point72 Asset Management, L.P. 5.5% $44,930,777 2,781,902 Point72 Asset Management, L.P. 05 Jan 2026
Vestal Point Capital, LP 1.5% $9,135,000 750,000 Vestal Point Capital, LP 30 Sep 2025

As of 31 Dec 2025, 160 institutional investors reported holding 66,956,279 shares of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV). This represents 132% of the company’s total 50,580,036 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) together control 112% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VR ADVISER, LLC 13% 6,728,985 0% 5.4% $108,673,108
Frazier Life Sciences Management, L.P. 10% 5,039,867 0% 2.2% $81,393,852
SUVRETTA CAPITAL MANAGEMENT, LLC 9.4% 4,768,712 0% 1.9% $77,014,699
TANG CAPITAL MANAGEMENT LLC 9% 4,573,530 -9.3% 3.6% $73,862,510
BlackRock, Inc. 7.4% 3,754,148 +20% 0% $60,629,492
MILLENNIUM MANAGEMENT LLC 5.7% 2,896,666 +38% 0.03% $46,781,156
Capital World Investors 5.6% 2,808,583 -12% 0.01% $45,358,615
VANGUARD GROUP INC 5% 2,509,020 +0.32% 0% $40,520,674
SILVERARC CAPITAL MANAGEMENT, LLC 4.8% 2,427,118 +78% 5.7% $39,197,956
Point72 Asset Management, L.P. 4.5% 2,283,766 0.06% $36,882,821
Woodline Partners LP 3.8% 1,921,092 +0.02% 0.12% $31,025,636
STATE STREET CORP 3.8% 1,911,691 +21% 0% $30,873,810
Vestal Point Capital, LP 3.7% 1,890,000 +152% 1.1% $30,523,500
Kynam Capital Management, LP 3.6% 1,810,954 +199% 1.9% $29,246,907
Parkman Healthcare Partners LLC 3.5% 1,768,508 +1.9% 2.7% $28,561,404
EMERALD ADVISERS, LLC 2.7% 1,340,495 -0.8% 0.67% $21,648,994
Octagon Capital Advisors LP 2.5% 1,273,333 0% 2.6% $20,564,328
SCHRODER INVESTMENT MANAGEMENT GROUP 2.3% 1,171,755 +1.1% 0.01% $18,923,843
GEODE CAPITAL MANAGEMENT, LLC 1.9% 944,077 +1.7% 0% $15,251,132
EMERALD MUTUAL FUND ADVISERS TRUST 1.7% 855,461 -6.8% 0.67% $13,815,695
GOLDMAN SACHS GROUP INC 1.7% 835,304 -54% 0% $13,490,160
Elmind Capital, LP 1.6% 801,300 0% 3.8% $12,940,995
ARMISTICE CAPITAL, LLC 1.6% 800,000 0.32% $12,920,000
BARCLAYS PLC 1.4% 700,573 +21% 0% $11,314,253
MORGAN STANLEY 1.4% 700,227 +24% 0% $11,308,665

Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 66,956,279 $1,081,355,139 +$110,690,698 $16.15 160
2025 Q3 58,631,949 $714,167,775 +$51,926,556 $12.18 144
2025 Q2 54,445,883 $615,513,091 -$5,352,606 $11.30 138
2025 Q1 54,890,685 $633,782,153 +$5,364,849 $11.54 127
2024 Q4 55,190,249 $467,414,520 +$30,397,001 $8.47 129
2024 Q3 48,412,221 $560,958,769 +$549,019 $11.58 120
2024 Q2 48,235,227 $568,211,775 +$14,329,598 $11.78 118
2024 Q1 46,978,393 $557,162,578 +$117,921,974 $11.86 128
2023 Q4 36,983,052 $453,043,903 +$5,790,575 $12.25 92
2023 Q3 36,263,336 $349,220,877 +$17,912,528 $9.63 101
2023 Q2 34,451,516 $310,062,547 +$8,864,955 $9.00 93
2023 Q1 33,720,468 $265,039,035 -$7,240,065 $7.86 87
2022 Q4 33,810,837 $228,557,857 +$23,549,577 $6.76 88
2022 Q3 25,639,454 $372,024,783 +$16,611,056 $14.51 88
2022 Q2 24,252,971 $238,647,172 -$18,209,799 $9.84 84
2022 Q1 23,950,478 $353,046,504 -$11,733,222 $14.74 84
2021 Q4 23,784,064 $314,614,009 -$24,155,895 $13.23 93
2021 Q3 23,380,949 $408,241,803 -$21,548,932 $17.45 101
2021 Q2 24,320,398 $582,722,986 +$12,095,008 $23.96 108
2021 Q1 23,504,843 $603,806,496 +$241,335,972 $25.69 115
2020 Q4 14,665,664 $278,488,932 +$4,362,596 $18.99 79
2020 Q3 16,200,799 $203,913,450 +$2,818,589 $12.59 61
2020 Q2 15,986,858 $193,667,544 +$9,419,888 $12.10 72
2020 Q1 15,660,431 $119,795,221 +$17,243,054 $7.65 68
2019 Q4 13,721,637 $244,359,076 +$13,370,440 $17.81 73
2019 Q3 13,183,569 $152,927,098 -$33,989,311 $11.60 75
2019 Q2 14,786,402 $327,505,666 +$6,277,733 $22.15 74
2019 Q1 13,905,857 $397,892,000 +$23,850,655 $28.62 67
2018 Q4 12,995,790 $256,399,000 +$7,695,219 $19.75 56
2018 Q3 12,319,459 $272,385,000 +$112,676,598 $22.11 46
2018 Q2 6,316,266 $51,280,000 -$1,600,370 $8.12 24
2018 Q1 6,502,232 $61,590,000 +$133,882 $9.48 23
2017 Q4 6,484,043 $63,213,000 -$2,998,314 $9.75 23
2017 Q3 7,715,060 $52,230,000 +$2,314,839 $6.73 15
2017 Q2 7,368,527 $54,075,000 -$1,766,461 $7.36 17
2017 Q1 7,587,480 $59,162,000 +$2,023,038 $7.81 18
2016 Q4 7,331,083 $51,493,000 +$46,974,000 $7.07 18